We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00069719
First Posted: October 6, 2003
Last Update Posted: August 5, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Alcon Research
September 30, 2003
October 6, 2003
August 5, 2008
February 1999
August 2003   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00069719 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients
To determine the safety and IOP-lowering ability of a test compound in patients with open-angle glaucoma or ocular hypertension.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Open-Angle Glaucoma
  • Ocular Hypertension
Drug: Glaucoma therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
August 2003
August 2003   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension;
  • logMAR visual acuity not worse than 0.6.

Exclusion Criteria:

  • Clinically relevant ophthalmic or systemic conditions may be excluded.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00069719
C-02-33
C-02-33
Not Provided
Not Provided
Not Provided
Not Provided
Alcon Research
Not Provided
Not Provided
Alcon Research
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP